Véronique MICHEL

Professeure des Universités en Pharmacologie

Parcours professionnel

- Etudes de Pharmacie (1995-2002) / Diplôme d’Etat de Docteure en Pharmacie (2003)
Faculté de Pharmacie, Université Louis Pasteur – Strasbourg I
- Diplôme Inter-Universitaire de statistiques (DIU-CESAM) (2001)
Université Pierre et Marie Curie – Paris VI
- Doctorat d’Université (2002-2006) / Diplôme de Docteure d’Université (2006)
Discipline : Sciences Pharmaceutiques. Spécialité : Pharmacologie cellulaire et moléculaire

Université Louis Pasteur – Strasbourg I
- Stage post-doctoral (2006-2007) (ERS Long-Term Research Fellowship N° 154).
Respiratory Pharmacology Group, Airway disease section, Imperial College School of Medicine, National Heart and Lung Institute, Londres, Royaume-Uni.
- Associée de Recherche – Responsable d’équipe (2007-2008)
Equipe « Systèmes nerveux des voies aériennes », Respiratory Pharmacology Group, Airway disease section, Imperial College School of Medicine, National Heart and Lung Institute, Londres, Royaume-Uni.
- Maitresse de Conférences des Universités en Pharmacologie (2008-2019) CNU 86^ème Section
Université de Bordeaux, UFR des Sciences Pharmaceutiques, Collège Santé, Centre de Recherche Cardio-Thoracique de Bordeaux (Inserm U1045), Département Sciences & technologies pour la santé.
- Autorisation d’expérimentation animale Niveau 1 – niveau Concepteur (formation continue à jour) Formation à la chirurgie sur rongeurs
- Diplôme d’Habilitation à Diriger des Recherches (2016)
Spécialité : Sciences de la vie et de la santé, Université de Bordeaux
- Professeure des Universités en Pharmacologie (2019 à aujourd’hui) CNU 86^ème Section
Université de Bordeaux, UFR des Sciences Pharmaceutiques, Collège Santé, Centre de Recherche Cardio-Thoracique de Bordeaux (Inserm U1045), Département Sciences & technologies pour la santé.

Membres

Véronique MICHEL

Parcours professionnel

Publications 48

CXCR4 Blockade Alleviates Pulmonary and Cardiac Outcomes in Early COPD.

CXCR4 Blockade Alleviates Pulmonary and Cardiac Outcomes in Early COPD

Celastrol has beneficial effects on pulmonary hypertension associated with bronchopulmonary dysplasia: Preclinical study outcomes

Effects of the nerve growth factor and its carrier protein on the inflammatory response from human monocytes.

NGF increases Connexin-43 expression and function in pulmonary arterial smooth muscle cells to induce pulmonary artery hyperreactivity.

[Nerve growth factor (NGF) in pulmonary hypertension (PH)]

OP2113, a new drug for chronic hypoxia‐induced pulmonary hypertension treatment in rat

Inflammation and Oxidative Stress Induce NGF Secretion by Pulmonary Arterial Cells through a TGF-β1-Dependent Mechanism

Piezo1 Channel Activation Reverses Pulmonary Artery Vasoconstriction in an Early Rat Model of Pulmonary Hypertension: The Role of Ca2+ Influx and Akt-eNOS Pathway

Cell Confluence Modulates TRPV4 Channel Activity in Response to Hypoxia

NiONP-Induced Oxidative Stress and Mitochondrial Impairment in an In Vitro Pulmonary Vascular Cell Model Mimicking Endothelial Dysfunction

Implication des canaux mécanosensibles Piezo1 et TRPV4 dans l’hypertension pulmonaire

NiONPs-induced alteration in calcium signaling and mitochondrial function in pulmonary artery endothelial cells involves oxidative stress and TRPV4 channels disruption.

Mechanosensitivity in Pulmonary Circulation: Pathophysiological Relevance of Stretch-Activated Channels in Pulmonary Hypertension

Effects of FW2 Nanoparticles Toxicity in a New In Vitro Pulmonary Vascular Cells Model Mimicking Endothelial Dysfunction.

Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease.

[The expression and role of nerve growth factor (NGF) in pulmonary hypertension].

Altered vasoreactivity in neonatal rats with pulmonary hypertension associated with bronchopulmonary dysplasia: Implication of both eNOS phosphorylation and calcium signaling

Calcium signalling induced by in vitro exposure to silicium dioxide nanoparticles in rat pulmonary artery smooth muscle cells

Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease

CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension

Involvement of Heme Oxygenase-1 in particulate matter-induced impairment of NO-dependent relaxation in rat intralobar pulmonary arteries

Expression and role of connexin-based gap junctions in pulmonary inflammatory diseases

Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension

Mitochondria: Roles in pulmonary hypertension

Characterization of the components of urban particulate matter mediating impairment of nitric oxide-dependent relaxation in intrapulmonary arteries

Reactive oxygen species as therapeutic targets in pulmonary hypertension

Biopterin Metabolism and eNOS Expression during Hypoxic Pulmonary Hypertension in Mice

Do beta(2)-agonists inhibit capsaicin-induced cough?

Hypoxia-induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors

beta(2)-Agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway

TRPA1 Agonists Evoke Coughing in Guinea Pig and Human Volunteers

Modulation of cholinergic contractions of airway smooth muscle by cathinone: potential beneficial effects in airway diseases

Overexpression of functional TrkA receptors after internalisation in human airway smooth muscle cells

The nerve growth factor and its receptors in airway inflammatory diseases

Inhibitory activity of the novel CB(2) receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways

Anti-proliferative effect of Euphorbia stenoclada in human airway smooth muscle cells in culture

[Nerve growth factor (NGF): new role for a neuronal mediator in the airways]

Inflammatory conditions increase expression of protease-activated receptor-2 by human airway smooth muscle cells in culture

TrkA signalling pathways in human airway smooth muscle cell proliferation

Nerve growth factor and its receptors in asthma and inflammation.

[Nerve growth factor (NGF) in inflammation and asthma]

Expression of nerve growth factor in the airways and its possible role in asthma.

Transforming growth factor-beta and its role in asthma

[Dust mite allergens in carpet: comparison between offices and bedrooms]

Upregulation of nerve growth factor expression by human airway smooth muscle cells in inflammatory conditions

[Nerve growth factor (NGF): a novel mediator in inflammation and asthma?]

Nerve growth factor secretion by human lung epithelial A549 cells in pro- and anti-inflammatory conditions

Équipe

Physiopathologie de la circulation pulmonaire